他汀类药物结合沙库巴曲缬沙坦对冠心病患者的效果  

Outcomes of Statins Combined with Sacubitril Valsartan in Patients with Coronary Artery Disease

作　　者：吴春霞 WU Chunxia(Affiliated Hospital of Putian University,Putian 351100,China)

机构地区：[1]莆田学院附属医院,福建莆田351100

出　　处：《中外医学研究》2024年第27期57-61,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:分析他汀类药物结合沙库巴曲缬沙坦对冠心病(CHD)患者的效果。方法:选取莆田学院附属医院2022年6月—2023年7月收治的89例CHD患者作为研究对象,按随机数表法分为参照组(44例)和研究组(45例)。参照组实施他汀类药物治疗,研究组在上述基础上实施沙库巴曲缬沙坦治疗。分析两组血脂指标、炎症因子指标、血管内皮功能及硬度。结果:治疗前,两组血脂指标比较,差异无统计学意义(P>0.05);治疗后,研究组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)指标明显低于参照组,高密度脂蛋白(HDL-C)明显高于参照组,差异有统计学意义(P<0.05)。治疗前,两组炎症因子指标比较,差异无统计学意义(P>0.05);治疗后,研究组炎症指标均明显低于参照组,差异有统计学意义(P<0.05)。治疗前,两组血管内皮功能及硬度比较,差异无统计学意义(P>0.05);治疗后,研究组肱动脉内皮依赖性舒张功能(FMD)指标明显高于参照组,内皮素-1(ET-1)明显低于参照组,差异有统计学意义(P<0.05)。结论:CHD经他汀类药物结合沙库巴曲缬沙坦治疗可获得较高价值,不仅能够调节血脂水平,还可有效降低炎症指标,改善血管内皮功能。Objective:To analyze the results of statins combined with sacubitril valsartan in patients with coronary heart disease(CHD).Method:A total of 89 CHD patients admitted to the Affiliated Hospital of Putian University from June 2022 to July 2023 were selected as the study objects,and were divided into the reference group(44 cases)and the study group(45 cases)according to random number table method.Patients in the reference group were treated with statins,and patients in the study group were treated with sakubactril and valsartan on the basis of the above.Blood lipid index,inflammatory factor index,vascular endothelial function and hardness of the two groups were analyzed.Result:Before treatment,there was no significant difference in blood lipid indexes between the two groups(P>0.05).After treatment,the indexes of total cholesterol(TC),triglyceride(TG)and low-density lipoprotein(LDL-C)in the study group were significantly lower than those in the reference group,and high density lipoprotein(HDL-C)was significantly higher than that in the reference group,with statistical significance(P<0.05).Before treatment,there was no significant difference in inflammatory factors between the two groups(P>0.05).After treatment,the inflammation indexes in the study group were significantly lower than those in the reference group,and the difference was statistically significant(P>0.05).After treatment,the inflammation indexes in the study group were significantly lower than those in the reference group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in vascular endothelial function and hardness between the two groups(P>0.05).After treatment,the index of brachial artery endothelium-dependent diastolic function(FMD)in the study group was significantly higher than that in the reference group,and endothelin-1(ET-1)was significantly lower than that in the reference group,with statistical significance(P<0.05).Conclusion:The treatment of CHD with statin combined with sacubactril a

关 键 词：他汀类药物 沙库巴曲缬沙坦 冠心病 血脂水平 炎症因子 血管内皮功能 

分 类 号：R541.4[医药卫生—心血管疾病]